We are proud to be the first AI healthcare company in Southeast Asia to receive US FDA clearance for DrAid™ Radiology v1 since September 2022. With our mission to integrate AI and IoT into healthcare to improve people's lives and productivity, we’re at the forefront of making social impacts by addressing the most critical challenges for global healthcare: Tuberculosis and Liver Cancer.

As the sole entity selected by the Global Fund to transfer AI technology for tuberculosis screening as part of Vietnam's National Tuberculosis (TB) Control Programme in 2024, we aim to screen 1 million suspected TB cases in Vietnam. DrAid ™ for TB Screening has recently launched a version dedicated for children with a sensitivity of 90.76% and specificity of 89.45% (exceeding WHO criteria by 20 points in specificity).
What's more?